113 related articles for article (PubMed ID: 14755890)
1. Defining the human targets of phorbol ester and diacylglycerol.
Geiger M; Wrulich OA; Jenny M; Schwaiger W; Grunicke HH; Uberall F
Curr Opin Mol Ther; 2003 Dec; 5(6):631-41. PubMed ID: 14755890
[TBL] [Abstract][Full Text] [Related]
2. Differential membrane binding and diacylglycerol recognition by C1 domains of RasGRPs.
Johnson JE; Goulding RE; Ding Z; Partovi A; Anthony KV; Beaulieu N; Tazmini G; Cornell RB; Kay RJ
Biochem J; 2007 Sep; 406(2):223-36. PubMed ID: 17523924
[TBL] [Abstract][Full Text] [Related]
3. Selective binding of phorbol esters and diacylglycerol by individual C1 domains of the PKD family.
Chen J; Deng F; Li J; Wang QJ
Biochem J; 2008 Apr; 411(2):333-42. PubMed ID: 18076381
[TBL] [Abstract][Full Text] [Related]
4. Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain.
Rahman GM; Das J
J Biomol Struct Dyn; 2015; 33(1):219-32. PubMed ID: 24666138
[TBL] [Abstract][Full Text] [Related]
5. Diacylglycerol kinase gamma is one of the specific receptors of tumor-promoting phorbol esters.
Shindo M; Irie K; Ohigashi H; Kuriyama M; Saito N
Biochem Biophys Res Commun; 2001 Nov; 289(2):451-6. PubMed ID: 11716494
[TBL] [Abstract][Full Text] [Related]
6. New insights into the regulation of protein kinase C and novel phorbol ester receptors.
Ron D; Kazanietz MG
FASEB J; 1999 Oct; 13(13):1658-76. PubMed ID: 10506570
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties.
Kazanietz MG; Caloca MJ; Eroles P; Fujii T; García-Bermejo ML; Reilly M; Wang H
Biochem Pharmacol; 2000 Nov; 60(10):1417-24. PubMed ID: 11020443
[TBL] [Abstract][Full Text] [Related]
8. C1 domains exposed: from diacylglycerol binding to protein-protein interactions.
Colón-González F; Kazanietz MG
Biochim Biophys Acta; 2006 Aug; 1761(8):827-37. PubMed ID: 16861033
[TBL] [Abstract][Full Text] [Related]
9. Novel "nonkinase" phorbol ester receptors: the C1 domain connection.
Kazanietz MG
Mol Pharmacol; 2002 Apr; 61(4):759-67. PubMed ID: 11901214
[TBL] [Abstract][Full Text] [Related]
10. Ligand structure-activity requirements and phospholipid dependence for the binding of phorbol esters to protein kinase D.
Wang QJ; Fang TW; Yang D; Lewin NE; Van Lint J; Marquez VE; Blumberg PM
Mol Pharmacol; 2003 Dec; 64(6):1342-8. PubMed ID: 14645664
[TBL] [Abstract][Full Text] [Related]
11. Targeting protein kinase C and "non-kinase" phorbol ester receptors: emerging concepts and therapeutic implications.
Kazanietz MG
Biochim Biophys Acta; 2005 Dec; 1754(1-2):296-304. PubMed ID: 16202672
[TBL] [Abstract][Full Text] [Related]
12. [RasGRP proteins--Ras-activating factors].
Szamałek M; Baer-Dubowska W
Postepy Biochem; 2007; 53(2):112-20. PubMed ID: 17969871
[TBL] [Abstract][Full Text] [Related]
13. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters.
Brose N; Rosenmund C
J Cell Sci; 2002 Dec; 115(Pt 23):4399-411. PubMed ID: 12414987
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and phorbol ester binding of the cysteine-rich domains of diacylglycerol kinase (DGK) isozymes. DGKgamma and DGKbeta are new targets of tumor-promoting phorbol esters.
Shindo M; Irie K; Masuda A; Ohigashi H; Shirai Y; Miyasaka K; Saito N
J Biol Chem; 2003 May; 278(20):18448-54. PubMed ID: 12621060
[TBL] [Abstract][Full Text] [Related]
15. Development of diacyltetrol lipids as activators for the C1 domain of protein kinase C.
Mamidi N; Gorai S; Mukherjee R; Manna D
Mol Biosyst; 2012 Apr; 8(4):1275-85. PubMed ID: 22301880
[TBL] [Abstract][Full Text] [Related]
16. Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C).
Tamamura H; Sigano DM; Lewin NE; Peach ML; Nicklaus MC; Blumberg PM; Marquez VE
J Med Chem; 2004 Sep; 47(20):4858-64. PubMed ID: 15369389
[TBL] [Abstract][Full Text] [Related]
17. Divergence and complexities in DAG signaling: looking beyond PKC.
Yang C; Kazanietz MG
Trends Pharmacol Sci; 2003 Nov; 24(11):602-8. PubMed ID: 14607084
[TBL] [Abstract][Full Text] [Related]
18. PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors.
Oliva JL; Griner EM; Kazanietz MG
Growth Factors; 2005 Dec; 23(4):245-52. PubMed ID: 16338787
[TBL] [Abstract][Full Text] [Related]
19. Receptors and endogenous analogs for the phorbol ester tumor promoters.
Blumberg PM; Jeng AY; König B; Sharkey NA; Leach KL; Jaken S
Carcinog Compr Surv; 1985; 10():249-62. PubMed ID: 4064007
[No Abstract] [Full Text] [Related]
20. PKD at the crossroads of DAG and PKC signaling.
Wang QJ
Trends Pharmacol Sci; 2006 Jun; 27(6):317-23. PubMed ID: 16678913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
